HYPAQUE-CYSTO
LOE ApproachingNDAURETHRALSOLUTIONPriority Review
Approved
Aug 1969
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 2d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HYPAQUE-CYSTO is a urethral solution containing sodium diatrizoate, a contrast agent used for retrograde cystourethrography and related urological imaging procedures. Administered directly into the urethra, it enables visualization of the bladder and urethra during diagnostic imaging studies. The product is a legacy diagnostic agent approved in 1969 by GE HealthCare.
LOE Approaching
As a 55-year-old diagnostic agent approaching loss of exclusivity with moderate competitive pressure (30%), this product likely supports a small, maintenance-focused team with limited growth opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job openings and LOE approaching, career roles on HYPAQUE-CYSTO are limited to maintenance and transition functions. This is not a growth platform; roles focus on protecting market share and managing operational efficiency during decline.
Product ManagerField Sales
Worked on HYPAQUE-CYSTO at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.